Surmodics to Present at Canaccord Genuity Medical Technology and Diagnostics Forum

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will make a presentation to the investment community at the Canaccord Genuity Medical Technology and Diagnostics Forum in New York City on Thursday, November 17, 2016, at 8:20 a.m. ET (7:20 a.m. CT).
A live audio webcast of the presentation will be available by going to
the investor relations portion of the Company’s website at www.surmodics.com
and clicking on the webcast icon. The webcast will be archived on the
Company’s website for 90 days following the meeting.
About Surmodics, Inc.
Surmodics is the global leader in
surface modification technologies for intravascular medical devices and
a leading provider of chemical components for in vitro diagnostic
(IVD) tests and microarrays. Following two recent acquisitions of Creagh
Medical and NorMedix, the Company is executing a key growth strategy for
its medical device business by expanding to offer total intravascular
product solutions to its medical device customers. The combination of
proprietary surface technologies, along with enhanced device design,
development and manufacturing capabilities, enables Surmodics to
significantly increase the value it offers with highly differentiated
intravascular solutions designed and engineered to the most demanding
requirements. With this focus on offering total solutions, Surmodics’
mission remains to improve the detection and treatment of disease.
Surmodics is headquartered in Eden Prairie, Minnesota. For more
information about the company, visit www.surmodics.com.
The content of Surmodics’ website is not part of this press release or
part of any filings that the company makes with the SEC.